Last reviewed · How we verify
Placebo of ADC189 granules
Placebo of ADC189 granules is a Small molecule drug developed by Jiaxing AnDiCon Biotech Co.,Ltd. It is currently in Phase 3 development.
This is a placebo control formulation used in clinical trials and contains no active pharmaceutical ingredient.
At a glance
| Generic name | Placebo of ADC189 granules |
|---|---|
| Sponsor | Jiaxing AnDiCon Biotech Co.,Ltd |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo of ADC189 granules, this product is an inert comparator used in phase 3 clinical trials to establish the efficacy and safety of the active ADC189 drug through blinded comparison. Placebos serve as the control arm to distinguish genuine therapeutic effects from natural disease progression or patient expectation effects.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of ADC189 granules CI brief — competitive landscape report
- Placebo of ADC189 granules updates RSS · CI watch RSS
- Jiaxing AnDiCon Biotech Co.,Ltd portfolio CI